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Abstract 
Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease 
areas.  Extensive studies to dissect the mechanisms of insulin resistance have provided valuable 
insights to shape current clinical awareness and advance therapeutic practice.  However, the 
development of direct interventions against insulin resistance have been hindered by its complex 
and highly variable presentations, especially in type 2 diabetes.   Amongst glucose-lowering agents, 
metformin and thiazolidinediones provide cellular actions that counter some effects of insulin 
resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve 
insulin action, excepting that endogenously- or exogenously-created hyperinsulinaemia may partially 
compromise these benefits.  Increasing awareness of the pervasive and damaging ramifications of 
insulin resistance heightens the need for more specifically targeted and more effective therapies.     
 
Introduction 
This short review is written in recognition of the seminal works of Gerald Reaven on the role of 
insulin resistance in the pathogenesis of type 2 diabetes and cardiovascular (CV) disease.  Foregoing 
reviews in this issue of Diabetes and Vascular Disease Research  have eminently recounted these 
works [1-4]. Here we consider how a growing appreciation of insulin resistance influenced the 
development of new therapeutics in the field of diabetes. 
 
Multifactorial pathophysiology 
Reaven’s Syndrome X (not to be confused with the cardiac syndrome X) describes the clustering of 
CV risk factors that depend on, or associate with insulin resistance [5].  Although Reaven’s Syndrome 
X later became subsumed within the so-called Metabolic Syndrome, the two syndromes are not 
synonymous:  insulin resistance can promote CV disease independently of other CV risk factors 
commonly included in the Metabolic Syndrome such as excess adiposity, and insulin resistance is 
often associated with compensatory hyperinsulinaemia, at least in its early pathogenesis, which 
further aggravates metabolic, vascular and haemodynamic disturbances [6, 7].  Studies on the 
aetiology of insulin resistance and accompanying metabolic and CV abnormalities gave rise to a 
‘common soil’ hypothesis of shared origins, and clinical practice recognised that the presence of one 
feature associated with insulin resistance should prompt suspicion about other CV risk factors [8].  
This in turn has promoted a more holistic multifactorial approach to the assessment and 
management of type 2 diabetes to accommodate metabolic and cardio-renal aspects [9, 10].   
Insulin resistance presents across a wide variety of phenotypes with different responses between 
tissues, organs and physiological systems.  Because this is typically due to multiple ‘bottle-necks’ in 
the signalling pathways that mediate the biological actions of insulin it has not been possible to 
Identify a single cure-all molecular target [2].   However, several glucose-lowering agents can 
ameliorate the effects of insulin resistance with impact on diabetic complications, particularly in 
type 2 diabetes (Figure 1).   
 
Insulin 
When Harold Himsworth described insulin resistance in the 1930s he energized debate about 
different types of diabetes [ 11 ].  Studies by Yalow and Berson in the late 1950s noted that insulin 
concentrations might actually be higher in the early stages of ‘maturity-onset diabetes’, which 
substantiated the Himsworth premise [12].  Indeed, excess insulin has been mooted as a possible 
atherogenic factor [13], and concern about the use of high doses of insulin therapy was highlighted 
by evidence that raised insulin concentrations do not rectify insulin resistance and may lead to an 
increasing spiral of insulin demand through further disruption to insulin receptor binding and post-
receptor signalling [14].  Thus, an appreciation of Syndrome X helped to redirect attention towards 
sparing insulin rather than increasing insulin, particularly in the earlier stages of type 2 diabetes.   
While this illustrates the rationale for changing the management focus of type 2 diabetes beyond 
insulin, the main alternative up to the 1990s was the use of sulfonylureas which act mostly by 
stimulating insulin secretion.  
 
Sulfonylureas 
The first sulfonylureas (eg carbutamide and tolbutamide) from the mid 1950s, and more potent 
versions from the mid 1960s (eg glibenclamide) have well-studied glucose-lowering properties in 
type 2 diabetes, but incur weight gain and risk of hypoglycaemia [15].  However, the effects of 
sulfonylureas on insulin resistance have not been consistent, and CV effects are also unclear.  The 
much criticised University Group Diabetes Program (UGDP) cast doubt on the CV safety of 
tolbutamide in the late 1960s [ 16 ],  but the United Kingdom Prospective Diabetes Study (UKPDS)  
and many other trials have shown a better CV prognosis  with sulfonylureas than diet/lifestyle but 
less beneficial than metformin [17, 18].  Similarly, the effects of meglitinides on insulin resistance 
and CV events remain unclear but appear minimal.  Nevertheless, the detrimental impact of 
hypoglycaemia on CV events and the adverse effects of insulin resistance on islet beta-cell function 
must be considered in selecting glucose-lowering therapies [19, 20].   
 
Biguanides 
Although several guanidine derivatives were used in the treatment of diabetes in the 1920s and 
1930s, their use dwindled as insulin became available, and it was not until the late 1950s that three 
biguanides (metformin, phenformin, and buformin) were introduced in Europe and one 
(phenformin) was introduced into the USA [21].  Phenformin and buformin were withdrawn in the 
late 1970s due to high risk of lactic acidosis, and metformin was eventually introduced into the USA 
in 1995.  Since biguanides lower blood glucose in type 2 diabetes without stimulating insulin 
secretion it was acknowledged that they counter insulin resistance, and this was initially attributed 
to increased anaerobic metabolism and an independent reduction of hepatic gluconeogenesis.  Lack 
of weight gain and low risk of hypoglycaemia favoured early use of metformin in type 2 diabetes, 
supported by mounting evidence for long-term reductions in CV disease [18, 22].  Through increased 
appreciation of the pathogenic effects of insulin resistance, Reaven’s studies contributed an 
important part of the scientific platform for metformin and its present-day position as first-line 
pharmacological therapy for type 2 diabetes.  Reaven’s group also conducted several key studies on 
the mode of action of metformin, for example showing the inter-relationship of effects on glucose 
and lipid homeostasis [23].  The group also noted that metformin prolongs insulin receptor tyrosine 
kinase activity [24].  
 
Thiazolidinediones 
Thiazolidinediones (TZDs) emerged from lipid-lowering clofibrate analogues in the mid 1970s, before 
peroxisome proliferator-activated receptor (PPAR) molecules had been discovered, but it was not 
until the late 1990s that the first PPARagonist (troglitazone) was introduced and then withdrawn 
due to unexplained hepatotoxicity.  Rosiglitazone and pioglitazone followed promptly: they lowered 
plasma glucose without raising insulin, mostly through genomic effects that include differentiation 
of new small insulin-sensitive subcutaneous adipocytes, and improved insulin action in liver and 
muscle [25].  Pioglitazone also has some PPAR agonism which assists lipid control, but weight gain 
associated with adipose deposition, renal effects to increase fluid retention and risk of heart failure 
limited their use.  Rosiglitazone was withdrawn in Europe in 2010 amid controversy over possible 
adverse CV effects, and potential risk of bone fractures has further limited use.  Although TZDs 
provided an antidote to insulin resistance, their limitations illustrate the complexities and 
ambiguities of increasing insulin action across a breadth of biological functions without modulating 
effects in different tissues [26].   
  
Incretins 
Emanating from studies of the entero-insular axis, the availability of glucagon-like peptide-1 receptor 
agonists (GLP-1RAs) from 2005 and dipeptidyl peptidase-4 (DPP4) inhibitors from 2006 shifted the 
therapeutic focus of type 2 diabetes back to the pancreas. These agents do not carry the risk of 
hypoglycaemia seen with sulfonylureas because they potentiate insulin secretion and suppress 
glucagon secretion in a glucose-dependent manner (sulfonylureas stimulate insulin secretion 
independently of the glucose concentration) [27, 28].  Interestingly, GLP-1 RAs and DPP4 inhibitors 
reduce insulin resistance:  this appears to be due, at least in part, to a lowering of glucose 
concentrations, interrupting the vicious spiral of type 2 diabetes in which insulin resistance 
generates hyperglycaemia and the ensuing glucotoxicity aggravates insulin resistance [20].  The 
satiety effect of GLP-1RAs, which is associated with weight loss and decreased adiposity, provides 
further metabolic and endocrine mechanisms to reduce insulin resistance, and potential additional 
incretin-based therapies including peptide YY (PYY), oxyntomodulin, derivatives of gastric inhibitory 
polypeptide (GIP) and antagonists of ghrelin are under investigation [29].    
  
Sodium/glucose co-transporter-2 (SGLT2) inhibitors  
SGLT2 inhibitors introduced in 2012 reduce glucotoxicity and adiposity by eliminating excess glucose 
in the urine, and thereby act indirectly to reduce insulin resistance and spare some of the demand 
on beta-cell function [30, 31].  Further evidence that lowering blood glucose will in turn lower insulin 
resistance is provided by alpha-glucosidase inhibitors which reduce prandial glucose excursions by 
slowing the rate of carbohydrate digestion.    
 
Adipose and anti-obesity agents to reduce weight 
Excess lipids, endocrine factors and pro-inflammatory molecules from adipose tissue are well known 
to promote the pathogenesis of insulin resistance in obese type 2 diabetes, and several adipokine-
based therapies such as adiponectin receptor agonists are receiving consideration as potential 
approaches to counter insulin resistance.  Improvements of insulin action and glycaemic control are 
consistently reported with caloric restriction and reduced adipose mass (particularly in omental, 
hepatic and pancreatic locations), whether achieved by dieting, bariatric procedures, SGLT2 
inhibitors, GLP-1RAs or other appetite/satiety-modifying therapies [32, 33].  We may wonder why 
the age-old energy-reducing approach to treating obese-diabetes has taken so long to regain 
prominence.   
 
Cardiovascular and other considerations  
It is perhaps an irony that one of the TZDs (rosiglitazone), which improved insulin sensitivity and 
reduced a range of atherogenic risk markers, should have triggered CV safety concerns and 
prompted current regulatory requirements for specific and extensive evaluation of CV events with 
new glucose-lowering agents [26].  Although there are many unanswered questions regarding the 
subtle interplay of insulin resistance and hyperinsulinaemia on the endothelium and myocardium, it 
is evident that early intervention to achieve long-term metabolic control and reduce insulin 
resistance provides an opportunity to improve CV prognosis [18, 26].  Timing appears to be 
especially important in this context because late interventions have been less successful against CV 
disease. The early development of hyperinsulinaemia with insulin resistance may promote 
hyperfiltration and damage to glomeruli, and insulin resistance is implicated in a wide variety of 
conditions including polycystic ovary syndrome and dementia indicating the breadth of potential 
benefits to be gained from effective timely interventions [1-4, 34, 35].      
  
Future 
Awareness of insulin resistance as an underlying and modifiable pathogenic factor spanning 
diabetes, CV and other disease areas makes it an important therapeutic target. However, despite 
considerable appreciation of insulin-receptor interactions and post-receptor signalling, therapeutic 
interventions have been unable to rectify or circumvent the complex multi-dimensional defects of 
insulin resistance [35].  Several current therapies do act, at least in part, to address the metabolic 
disturbances and provide some protection against adverse CV events associated with type 2 
diabetes, but it is unclear how these interventions will impact other disease areas susceptible to 
insulin resistance.  New therapeutic approaches, including small non-peptide molecules that partially 
mimic insulin effects at the insulin receptor, or initiate or potentiate receptor tyrosine kinase activity 
or target post-receptor pathways have been identified, but these are still at early stages of 
investigation [36 ].    Thus the therapeutic reversal of insulin resistance seems destined to be an 
ongoing unmet need for the foreseeable future. 
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Legend to figure 
Figure 1.   Timeline of some key events regarding insulin resistance and the introduction of diabetes 
therapies.   Metformin was introduced in the USA in 1995.  CSII, continuous subcutaneous insulin 
infusion; CV, cardiovascular; DPP-4is, dipeptidyl peptidase-4 inhibitors; GLP-1RAs, glucagon-like 
peptide-1 receptor agonists; PCOS, polycystic ovary syndrome; SGLT-2is, sodium/glucose 
cotransporter-2 inhibitors; TZDs, thiazolidinediones.    
 
 
 
 
 
 
